Full Text:
<1954>
Summary: 
<1710>
Suppl. Mater.: 
CLC number: R735.7
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2019-09-12
Cited: 0
Clicked: 4358
Integrated analysis of hypoxia-induced miR-210 signature as a potential prognostic biomarker of hepatocellular carcinoma: a study based on The Cancer Genome Atlas
| ||||||||||||||
Yi Dai, Ji-liang Shen, Xue-yong Zheng, Tian-yu Lin, Hai-tao Yu. Integrated analysis of hypoxia-induced miR-210 signature as a potential prognostic biomarker of hepatocellular carcinoma: a study based on The Cancer Genome Atlas[J]. Journal of Zhejiang University Science B, 2019, 20(11): 928-932.
@article{title="Integrated analysis of hypoxia-induced miR-210 signature as a potential prognostic biomarker of hepatocellular carcinoma: a study based on The Cancer Genome Atlas",
author="Yi Dai, Ji-liang Shen, Xue-yong Zheng, Tian-yu Lin, Hai-tao Yu",
journal="Journal of Zhejiang University Science B",
volume="20",
number="11",
pages="928-932",
year="2019",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1900343"
}
%0 Journal Article
%T Integrated analysis of hypoxia-induced miR-210 signature as a potential prognostic biomarker of hepatocellular carcinoma: a study based on The Cancer Genome Atlas
%A Yi Dai
%A Ji-liang Shen
%A Xue-yong Zheng
%A Tian-yu Lin
%A Hai-tao Yu
%J Journal of Zhejiang University SCIENCE B
%V 20
%N 11
%P 928-932
%@ 1673-1581
%D 2019
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1900343
TY - JOUR
T1 - Integrated analysis of hypoxia-induced miR-210 signature as a potential prognostic biomarker of hepatocellular carcinoma: a study based on The Cancer Genome Atlas
A1 - Yi Dai
A1 - Ji-liang Shen
A1 - Xue-yong Zheng
A1 - Tian-yu Lin
A1 - Hai-tao Yu
J0 - Journal of Zhejiang University Science B
VL - 20
IS - 11
SP - 928
EP - 932
%@ 1673-1581
Y1 - 2019
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1900343
Abstract: hepatocellular carcinoma (HCC) is one of the most common types of liver cancer and is the second leading cause of cancer mortality with an estimated 745 500 deaths annually (Jemal et al., 2011). Although new therapeutic modalities including novel chemotherapeutic interventions and targeted therapy have been applied, the prognosis of HCC patients remains unsatisfactory due to the high incidence of intrahepatic and distal metastases (Siegel et al., 2018).
[1]Airley RE, Mobasheri A, 2007. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy, 53(4):233-256.
[2]Bavelloni A, Ramazzotti G, Poli A, et al., 2017. MiRNA-210: a current overview. Anticancer Res, 37(12):6511-6521.
[3]https://doi.org/10.21873/anticanres.12107
[4]Brooks DL, Schwab LP, Krutilina R, et al., 2016. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models. Mol Cancer, 15:26.
[5]Heddleston JM, Li Z, Lathia JD, et al., 2010. Hypoxia inducible factors in cancer stem cells. Br J Cancer, 102(5): 789-795.
[6]Huang X, Le QT, Giaccia AJ, 2010. MiR-210—micromanager of the hypoxia pathway. Trends Mol Med, 16(5):230-237.
[7]Ivan M, Huang X, 2014. MiR-210: fine-tuning the hypoxic response. In: Koumenis C, Hammond E, Giaccia A (Eds.), Tumor Microenvironment and Cellular Stress: Signaling, Metabolism, Imaging, and Therapeutic Targets. Springer, New York, p.205-227.
[8]Jemal A, Bray F, Center MM, et al., 2011. Global cancer statistics. CA Cancer J Clin, 61(2):69-90.
[9]Kai AKL, Chan LK, Lo RCL, et al., 2016. Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology, 64(2):473-487.
[10]Liu LL, Li DH, He YL, et al., 2017. miR-210 protects renal cell against hypoxia-induced apoptosis by targeting HIF-1 alpha. Mol Med, 23:258-271.
[11]Pugh CW, Ratcliffe PJ, 2003. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med, 9(6):677-684.
[12]Semela D, Dufour JF, 2004. Angiogenesis and hepatocellular carcinoma. J Hepatol, 41(5):864-880.
[13]Siegel RL, Miller KD, Jemal A, 2018. Cancer statistics, 2018. CA Cancer J Clin, 68(1):7-30.
[14]Silakit R, Kitirat Y, Thongchot S, et al., 2018. Potential role of HIF-1-responsive microRNA210/HIF3 axis on gemcitabine resistance in cholangiocarcinoma cells. PLoS ONE, 13(6):e0199827.
[15]Wan LL, Zhang DQ, Zhang JN, et al., 2017. Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICA. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 18(6):522-531.
[16]Wang LY, Zheng SS, 2018. Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 19(7):497-504.
[17]Wang ZD, Qu FY, Chen YY, et al., 2017. Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 18(1):27-36.
[18]Yang Y, Zhang J, Xia T, et al., 2016. MicroRNA-210 promotes cancer angiogenesis by targeting fibroblast growth factor receptor-like 1 in hepatocellular carcinoma. Oncol Rep, 36(5):2553-2562.
[19]Ying Q, Liang LH, Guo WJ, et al., 2011. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology, 54(6):2064-2075.
[20]List of electronic supplementary materials
[21]Table S1 Clinicopathological parameters of the patients
[22]Table S2 Univariate and multivariate analyses of survival in 424 patients with HCC according to clinicopathologic factors and miR-210 expression
ORCID: 
Open peer comments: Debate/Discuss/Question/Opinion
<1>